SavedAdd your journal

Journals / Türk Psikiyatri Dergisi / 2017 / Cilt: 28 - Sayı: 2

Response With Methylphenidate to ADHD-Like Symptoms in Pervasive Developmental Disorder: Does CES-1 Enzyme Gene Polymorphism Have a Role?

Yaygın Gelişimsel Bozukluklarda Dikkat Eksikliği Hiperaktivite Bozukluğu Semptomlarına Metilfenidatla Yetersiz Yanıt: CES-1 Polimorfizminin Rolü Var mı?

Ülkü AKYOL ARDIÇ
EYÜP SABRİ ERCAN
DUYGU DÖNDÜ AYGÜNEŞ JAFARI
DENİZ YÜCE
Sibel DURAK
BUKET KOSOVA
Pages
89–94
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: This is the first study that an association between Arg199/His polymorphism in CES1 and altered treatment response to MPH in patients with PDD that presents with symptoms of ADHD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Methylphenidate is the first-choice medication for the Pervasive Developmental Disorders (PDDs), and comorbid Attention Deficit Hyperactivity Disorder (ADHD).
📊
Key Findings & Data:But this approach generally results with poor outcomes, and increased adverse effects.
💡
Conclusion & Impact:Conclusion: This is the first study that an association between Arg199/His polymorphism in CES1 and altered treatment response to MPH in patients with PDD that presents with symptoms of ADHD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Methylphenidate is the first-choice medication for the Pervasive Developmental Disorders (PDDs), and comorbid Attention Deficit Hyperactivity Disorder (ADHD). But this approach generally results with poor outcomes, and increased adverse effects. It is aimed to investigate the comparison of cases who diagnosed with PDDs and Mild Mental Retardation (MR) and cases with pure ADHD in terms of the clinical response to MPH. Also we aimed to investigate the relations between CES-1 polymorphism gene and the clinical response to MPH.Methods: For clarifying this we searched for three polymorphisms (Arg199/His, Ser75/Asn, and Ile49/Val) in carboxylesterase-1 gene (CES-1) in the saliva of patients diagnosed with PDD+ADHD. Also, we assessed the clinical response to MPH by dimensional approach using the Attention Deficit Hyperactivity Disorder Rating Scale IV and Clinical Global Impression-Improvement scale. Results: PDD+ADHD groups had significantly higher Arg199/His polymorphism, and clinically responded poorer with symptoms sometimes even worsening to the MPH treatment compared with "pure" ADHD and ADHD+MR groups. Conclusion: This is the first study that an association between Arg199/His polymorphism in CES1 and altered treatment response to MPH in patients with PDD that presents with symptoms of ADHD.

Özet

Amaç: Yaygın Gelişimsel Bozukluklar (YGB) ve eşlik eden Dikkat Eksikliği Hiperaktivite Bozukluğu (DEHB) belirtileri olan olgularda Metilfenidat (MPH) ilk tedavi seçeneği olmakla birlikte, sadece DEHB olan olgulara göre daha fazla yan etkiye yol açabildiği ve klinik yanıtın çok değişken olabileceği bilinmektedir. Bu çalışmanın amacı YGB ve Hafif Düzey Mental Retardasyonu (MR) olan olguların MPH'a yanıtı- nın yalnızca DEHB olan olgularla karşılaştırılması ve CES-1 gen polimorfizmleriyle ilişkisinin bulunup bulunmadığının belirlenmesidir. Yöntem: YGB ve eşlik eden DEHB varlığında tükürük örneği alınarak MPH'ı metabolize eden enzim olan Karboksilesteraz-1 (CES-1) polimorfizmleri (Arg199/His, Ser75/Asn ve Ile49/Val) incelenmiş olup MPH yanıtı Dikkat Eksikliği ve Yıkıcı Davranış Bozuklukları için DSM-IV'e Dayalı Tarama ve Değerlendirme Ölçeği ve Klinik Global İzlem Ölçeği ile değerlendirilmiştir. Bulgular: YGB ve eşlik eden DEHB varlığında olguların, DEHB, DEHB ve eşlik eden Hafif Düzey Zeka Geriliği olan olgulara göre daha kötü MPH yanıtı verdikleri ve CES-1'de Arg199/His polimorfizminin istatistiksel olarak anlamlı oranda yüksek olduğu bulunmuştur. Sonuç: Bu çalışma YGB ve eşlik eden DEHB olan olgularda CES-1 Arg199/His polimorfizminin incelendiği ilk çalışmadır.

🔖

Cite This Article

ARDIÇ, Ü. A., ERCAN, E. S., JAFARI, D. D. A., YÜCE, D., DURAK, S., KOSOVA, B. (2017). Response With Methylphenidate to ADHD-Like Symptoms in Pervasive Developmental Disorder: Does CES-1 Enzyme Gene Polymorphism Have a Role?. Türk Psikiyatri Dergisi, Cilt: 28 - Sayı: 2, 89–94. https://ajindex.com/articles/91633

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC. Bruxel EM, Salatino-Oliveira A, Genro JP ve ark. (2013) Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate. Pharmacogenomics J 13:476-480.
  2. Cortese S, Castelnau P, Morcillo C ve ark (2012) Psychostimulants for ADHDlike symptoms in individuals with autism spectrum disorders. Expert Rev Neurother 12:461-73.
  3. Di Martino A, Melis G, Cianchetti C ve ark (2004) Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. J Child Adolesc Psychopharmacol 14: 207-218.
  4. Ercan ES, Amado S, Somer O, Çıkoğlu S(2001) Dikkat Eksikliği Hiperaktivite Bozukluğu ve Yıkıcı Davranış Bozuklukları için bir Test Bataryası Geliştirme Çalışması. Çocuk ve Gençlik Ruh Sağlığı Dergisi 8:132-145.
  5. Frazier JA, Biederman J, Bellordre CA ve ark (2001) Should the Diagnosis of Attention Deficit/ Hyperactivity Disorder be Consider in Children with Pervasive Developmental Disorder? J Atten Disord 4:203-211.
  6. Goldstein S, Schwebach AJ (2004) The comorbidity of Pervasive Developmental Disorder and Attention Deficit Hyperactivity Disorder: results of a retrospective chart review. J Autism Dev Disord 34:329-39.
  7. Gökler B, Ünal F, Pehlivantürk B ve ark. (2004) Okul çağı çocukları için duygulanım bozuklukları ve şizofreni görüşme çizelgesi - şimdi ve yaşam boyu şekli-Türkçe uyarlamasının geçerlik ve güvenirliği. Çocuk ve Gençlik Ruh Sağlığı Dergisi 11:109-116.
  8. Grzadzinski R, Di MA, Brady E ve ark. (2011) Examining autistic traits in children with ADHD: does the autism spectrum extend to ADHD? J Autism Dev Disord 41:1178-1191.
  9. Guy W (1976) Clinical global impressions. ECDEU assessment manual for psychopharmacology, revised National Institute of Mental Health, Rockville, MD, s. 218-21.
  10. Johnson KA, Barry E, Lambert D ve ark. (2013) Methylphenidate Side Effect Profile Is Infuenced by Genetic Variation in the AttentionDeficit/Hyperactivity Disorder-Associated CES1 Gene. J Child Adolesc Psychopharmacol 10:655-664.
  11. Kaufman J, Birmaher B, Brent D ve ark. (1997) Schedule for affective disorders and schizophrenia for schoolage children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988.
  12. Lee DO, Ousley OY (2006) Atten